GLP ‐ 1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis
The FASEB Journal · 31.08.2025 · 39 (16)
DOI: 10.1096/fj.202501605r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 15.08.2025. Verfasst von Jiao Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Mitochondria, Ketosis, Polycystic Kidney, Autosomal Dominant, Glycolysis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), U.S. Department of Defense (DOD), HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM).
Abstract (Originalsprache)
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) are a class of medications that mimic the actions of the hormone GLP‐1, conferring beneficial effects on weight management and other metabolic conditions. However, whether GLP‐1RA plays a kidney‐protective action in ADPKD remains unknown. In this study, we define the role and mechanisms of one of the most popular GLP‐1RA agonists, Semaglutide, in ADPKD. We show that the expression of GLP‐1R is decreased in Pkd1 mutant renal epithelial cells and kidneys. Treatment with Semaglutide delays cyst growth in aggressive and long‐lasting Pkd1 mutant mouse models. Treatment with Semaglutide (1) decreases glucose uptake, ATP generation, and glycolysis, (2) deactivates PKD‐associated signaling pathways, including Rb, S6, and Stat3, resulting in a decrease in cell proliferation, (3) deactivates NF‐kB signaling pathways, resulting in a decrease in the expression of cytokines and the recruitment of macrophages, (4) normalizes mitochondrial morphology and function, (5) induces Pkd1 mutant renal epithelial cell death, (6) induces ketosis characterized by an increase in serum level of beta‐hydroxybutyrate (BHB) and the activation of AMPK, and (7) alleviates renal fibrosis through deactivation of TGF‐b signaling in Pkd1 mutant mouse kidneys. This study highlights the potential of GLP‐1R agonists as a novel therapeutic strategy for ADPKD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Nephrology, Renhe Hospital, Three Gorges University, Yichang, China.
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, USA.
Förderung
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- U.S. Department of Defense (DOD)
- HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM)
- NIDDK NIH HHS
- Health Science and Technology Project of China Hubei Province
- American Heart Association (AHA)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Division of Diabetes, Endocrinology, and Metabolic Diseases
Zitieren
APA
Wu, J., Cheng, A. S., Weimbs, T., Harris, P. C., Zhou, J. X., & Li, X. (2025). GLP ‐ 1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis. The FASEB Journal, 39(16). https://doi.org/10.1096/fj.202501605r
Vancouver
Wu J, Cheng AS, Weimbs T, Harris PC, Zhou JX, Li X. GLP ‐ 1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis. The FASEB Journal. 2025;39(16). doi:10.1096/fj.202501605r
BibTeX
@article{Wu2025,
author = {Wu, Jiao and Cheng, Alice Shasha and Weimbs, Thomas and Harris, Peter C and Zhou, Julie Xia and Li, Xiaogang},
title = {GLP ‐ 1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis},
journal = {The FASEB Journal},
year = {2025},
volume = {39},
number = {16},
doi = {10.1096/fj.202501605r}
}
EUVIMED